Annual Reviews Are Lazy — Here’s How to Actually Learn From Your Work
Do post-mortems — and even pre-mortems — regularly, not just annually, to learn and keep your team aligned.
What we’ve been getting wrong about AI’s truth crisis
This story originally appeared in The Algorithm, our weekly newsletter on AI. To get stories like this in your inbox first, sign up here. What would it take to convince you that the era of truth decay we were long warned about—where AI content dupes us, shapes our beliefs even when we catch the lie, and…
5 High-Growth Markets Where You Can Build Substantial Wealth in 2026
Here are five emerging markets poised for breakout growth in 2026.
Why My Need to Control Everything Was Holding My Team Back
When the most dependable person in the room becomes the bottleneck, growth stalls.
Spend Less and Stay Productive with This MacBook Air for Less Than $250
Solid performance for anyone on a budget.
I Failed My First Startup — Here’s How I Pivoted Without Losing Momentum
Through all my pivots, one thing became clear: maintaining momentum depends on having options
SoftBank stays in as Meesho $606M IPO becomes India’s first major e-commerce listing
Meesho heads for India’s first big e-commerce IPO next week.
How OpenAI and Google see AI changing go-to-market strategies
AI is changing how investors and startups bring their products to market. Three experts offered their insights at TechCrunch Disrupt.
The race to regulate AI has sparked a federal vs state showdown
The fight over AI regulation isn’t about the technology — it’s about whether Washington or the states get to set the rules, and what happens to consumers caught in between.
Microsoft Office for Windows Drops to Less Than $35 to Support Smoother Business Workflows
This lifetime license deal saves you $185.
The Download: the mysteries surrounding weight-loss drugs, and the economic effects of AI
This is today’s edition of The Download, our weekday newsletter that provides a daily dose of what’s going on in the world of technology. What we still don’t know about weight-loss drugs Weight-loss drugs have been back in the news this week. First, we heard that Eli Lilly, the company behind Mounjaro and Zepbound, became the first…